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Analyses of clinical prognostic factors in the treatment of advanced 
non-small cell lung cancer (NSCLC): Cox regression analysis based 
on 789 patients from three consecutive randomized Phase II trials 
using gemcitabine and docetaxel
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Background: The results concerning treatment efﬁcacy and toxicity of 
the three studies have been in part been presented in Clin Lung Cancer 
2005, 7: 208-214 and 2007, 8: 245-251 and at WCLC (2005, Abstract 
# 1297). Gemcitabine or docetaxel was either applied in patients with 
advanced NSCLC as single agents in different schedules and doses 
or as a platinum free doublet. Aim of this retrospective analysis is the 
identiﬁcation of clinical factors inﬂuencing the patient prognosis. 
Methods: Commonly used patients eligibility criteria included histo-
logically conﬁrmed stage “wet IIIB” with malignant pleural effusion or 
stage IV, WHO performance status (PS) 0-2, and no previous chemo-
therapy. As a result, overall survival was similar in all three studies. 
Of the 819 patients enrolled in 1998-2004 in the three studies 798 
were evaluable for this analysis: 85% of patients had stage IV disease 
and WHO performance status PS≤1. Univariate as well as stepwise 
multivariate Cox regression analyses were performed to evaluate the 
measure of impact for baseline characteristics and quality of life on 
overall survival. 
Results: Four factors have shown a signiﬁcant impact on overall 
survival: the laboratory parameters hemoglobin and LDH (p<0.0001), 
WHO performance status (PS) (p=0.001) and the quality of life mea-
sure for lung cancer of the EORTC, lung cancer questionnaire LC13, 
(p=0.0006), respectively (see table). 
Multivariate Cox Regression Analysis 
Factors associated with prognostic power Hazard-ratio P-value
WHO PS2 (vs 0 or 1) 1.443 0.001
HGB < 11 g/dL (vs 11 g/DL or more) 1.905 <0.0001
LDH 200 or more (vs < 200) 1.585 <0.0001
EORTC-LC13-Score > 1.5 (vs 1.5 or less) 1.365 0.0006
Male gender (vs female)* 1.201 0.0703
*Male gender (vs female) univariate 1.263 0.0085
If the gender was measured univariately the inﬂuence was also signiﬁ-
cant on overall survival (p=0.0085) but this factor has less impact in the 
setting of the multivariate model (p=0.07). The factor age discriminated 
dichotomously at 65 (<65 vs 65 and older) is not of prognostic value 
with overall survival (HR=0.92, p=0.39), as well as threefold discrimi-
nated baseline histology (adeno/sqamous/other) (HR=0.99, p=0.90). 
The examination of other factors as tumor stage (“wet IIIB” vs IV), the 
presence of extra-thoracic metastases, the number of co-morbidities, 
and surgical and radiological pretreatment also have shown no prognos-
tic inﬂuence on overall survival. As a matter of fact, the analysis for the 
effect of smoking on overall survival could not be performed since only 
few patients never smoked status. 
Conclusions: The retrospective analysis of our three consecutive stud-
ies in the treatment of NSCLC with gemcitabine or docetaxel conﬁrms 
the prognostic value of serum hemoglobin, and LDH, the WHO-per-
formance status, and the quality of life questionnaire LC13 measure as 
inﬂuential clinical determinants for overall survival.
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Biweekly docetaxel and gemcitabine as first line chemotherapy in 
advanced non small cell lung cancer (NSCLC)
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Background: The activity and tolerability of third-generation agents 
led many investigators to evaluate doublet combinations in the hope 
that platinum analogues could be eliminated from the treatment of 
advanced NSCLC. To improve the therapeutic index of this combina-
tion, we performed a study with biweekly gemcitabine and docetaxel. 
Primary objective was determination of objective response rate (ORR). 
Secondary objectives were time to progression, tolerability and overall 
survival. 
Methods: Patients histologically conﬁrmed of non-small cell lung 
cancer, aged > 18, ECOG PS 0-2, measurable lesion according 
RECIST criteria, adequate bone marrow, renal and hepatic function 
were included. Prior chemotherapy was not allowed. Patients received 
treatment with a combination of Docetaxel 50 mg/m2 and Gemcitabine 
2000 mg/m2 each 15 days for a maximum of 8 cycles. 
Results: Fifty patients were included between July 2005 and october 
2006.Now we present the results of the ﬁrst 45 patients:88 % were 
male, median age was 62,7 years old, 75% had ECOG 0-1 and 73 % of 
patients had stage IV. Histology was squamous cell carcinoma (53%) 
adenocarcinoma (31%) and large cell carcinoma (16%). A total 300 cy-
cles were administrated. Over 41 patients evaluable for response, none 
achieved CR, 16 PR (39%), 11 SD (27%) and 14 PD, with an overall 
response rate of 39%. Median follow up of patients is 19 months. 
Grade 3-4 toxicity per patient was: neutropenia (6%).Grade 1-2 toxicity 
per patient asthenia (75%), and nausea (30%). 
Conclusions: These results suggest that biweekly schedule of gem-
citabine / docetaxel is a safe and active regimen in ﬁrst line advanced 
NSCLC patients.Updated results will be presented
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gemcitabine (G) associated to docetaxel (D) or vinorelbine (V) for 
advanced non-small cell lung cancer (NSCLC): outcome data on a 
randomized phase II study
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